AMRX News and Press, Amneal Pharmaceuticals Inc. Class A

2024-06-15 11:19:01 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Eli Lilly and Company (LLY) Goldman Sac...

2024-06-12 12:51:54 ET More on Teva Pharmaceutical Teva Pharmaceutical: Buy This Bargain Before It's Gone Teva wins FDA nod for new Austedo formulation Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) ...

The Company’s leading R&D capabilities and robust, expanded manufacturing capacity are helping to address chronic market shortages Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of it...

Significantly expanding access to affordable, life-saving opioid overdose rescue medicine Entered distribution agreement with California; actively engaging with other states and municipalities to expand access Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” o...

2024-05-16 06:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. ...

2024-05-03 15:45:56 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript...

2024-05-03 13:37:08 ET Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Results Earnings Conference Call May 3, 2024, 08:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chi...

Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...

2024-05-03 06:02:55 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Amneal Pharmaceuticals Q1 2024 Earnings Preview FDA approves...

‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement...